Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance by Marta Araujo-Castro, Eider Pascual-Corrales, Javier Molina-Cerrillo, Teresa Alonso-Gordoa

Subjects: Get full text

Functional nanovesicles displaying anti-PD-L1 antibodies for programmed photoimmunotherapy by Hu Chen, Pengfei Zhang, Yesi Shi, Chao Liu, Qianqian Zhou, Yun Zeng, Hongwei Cheng, Qixuan Dai, Xing Gao, Xiaoyong Wang, Gang Liu

Subjects: Get full text

B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines by Sunhee Ji, Jaeyeon Lee, Eung Suk Lee, Dae Hee Kim, Jeong-Im Sin

Subjects: “…anti-pd-l1…”
Get full text

Modulating the tumor microenvironment improves antitumor effect of anti-PD-L1 mAb in breast cancer by Xiuying Li, Xianqin Luo, Shunqin Hu

Subjects: “…anti-pd-l1 mab…”
Get full text

Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase I... by Yuantai Li, Yu Min, Zhigong Wei, Zheran Liu, Yiyan Pei, Yujie Yang, Kun Gao, Ge Song, Shihong Xu, Shuangshuang He, Junyou Ge, Yan Qing, Youneng Wei, Ping Ai, Ye Chen, Xingchen Peng

Subjects: Get full text

Anti-PD-L1 Immunotherapy of Chronic Virus Infection Improves Virus Control without Augmenting Tissue Damage by Fibrosis by Valentina Casella, Paula Cebollada Rica, Jordi Argilaguet, Enric Vidal, María González-Cao, Roberto Güerri-Fernandez, Gennady Bocharov, Andreas Meyerhans

Subjects: Get full text

Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab by Erwin H.J. Tonk, Anne S.R. van Lindert, Joost J.C. Verhoeff, Karijn P.M. Suijkerbuijk

Subjects: Get full text

Combination therapy with probiotics and anti-PD-L1 antibody synergistically ameliorates sepsis in mouse model by Leiming Sun, Kun Fang, Zheng Yang

Subjects: Get full text

Health outcomes and budget impact projection of anti-PD-(L)1s in cancer care in Portugal by Luís Costa, Luís Costa, Teresa Alexandre, André Mansinho, Rita Sousa, Cláudia Vieira, Robert Hughes, Alexander Roediger, Sónia Matos Pereira, António Araújo

Subjects: “…anti-PD-(L)1…”
Get full text

Intratumoral nanofluidic system enhanced tumor biodistribution of PD‐L1 antibody in triple‐negative breast cancer by Hsuan‐Chen Liu, Simone Capuani, Andrew A. Badachhape, Nicola Di Trani, Daniel Davila Gonzalez, Robin S. Vander Pol, Dixita I. Viswanath, Shani Saunders, Nathanael Hernandez, Ketan B. Ghaghada, Shu‐Hsia Chen, Elizabeth Nance, Ananth V. Annapragada, Corrine Ying Xuan Chua, Alessandro Grattoni

Subjects: “…anti PD‐L1…”
Get full text

Improving anticancer effect of aPD-L1 through lowering neutrophil infiltration by PLAG in tumor implanted with MB49 mouse urothelial carcinoma by Guen Tae Kim, Eun Young Kim, Su-Hyun Shin, Hyowon Lee, Se Hee Lee, Ki-Young Sohn, Jae Wha Kim

Subjects: Get full text

New Fractional Cancer Mathematical Model via IL-10 Cytokine and Anti-PD-L1 Inhibitor by Esmehan Uçar, Necati Özdemir

Subjects: “…anti-PD-L1…”
Get full text

NHS-IL12 and bintrafusp alfa combination therapy enhances antitumor activity in preclinical cancer models by Chunxiao Xu, Bo Marelli, Jin Qi, Guozhong Qin, Huakui Yu, Hong Wang, Molly H. Jenkins, Kin-Ming Lo, Yan Lan

Subjects: Get full text

Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future? by Paolo A. Ascierto, Grant A. McArthur

Subjects: Get full text

Oxymatrine Inhibits PD-L1 by Downregulating IFN-γ to Promote Ferroptosis and Enhance Anti-PD-L1 Efficacy in Liver Cancer by Nong Y, Qin H, Wei L, Wei X, Lv J, Huang X, Wu B

Subjects: Get full text

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1? by Yaxiong Zhang, Huaqiang Zhou, Li Zhang

Subjects: Get full text

Real‐world efficacy of atezolizumab in non‐small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti‐PD‐1 antibody... by Naoki Furuya, Makoto Nishino, Kazushige Wakuda, Satoshi Ikeda, Takashi Sato, Ryota Ushio, Shigeru Tanzawa, Masafumi Sata, Kentaro Ito

Subjects: “…anti‐PD‐L1…”
Get full text

Combination of an autophagy inhibitor with immunoadjuvants and an anti-PD-L1 antibody in multifunctional nanoparticles for enhanced breast cancer immunotherapy by Yibin Cheng, Caixia Wang, Huihui Wang, Zhiwei Zhang, Xiaopeng Yang, Yanming Dong, Lixin Ma, Jingwen Luo

Subjects: Get full text

Safety and Efficacy of Concurrent Atezolizumab/Bevacizumab or Nivolumab Combination Therapy with Yttrium-90 Radioembolization of Advanced Unresectable Hepatocellular Carcinoma by Alexander Villalobos, Howard Hussein Dabbous, Olivia Little, Olumide Babajide Gbolahan, Mehmet Akce, Meghan Allegra Lilly, Zachary Bercu, Nima Kokabi

Subjects: Get full text

Therapeutic Anti-Tumor Efficacy of DC-Based Vaccines Targeting TME-Associated Antigens Is Improved When Combined with a Chemokine-Modulating Regimen and/or Anti-PD-L1 by Jennifer L. Taylor, Kathleen M. Kokolus, Per H. Basse, Jessica N. Filderman, Chloe E. Cosgrove, Simon C. Watkins, Andrea Gambotto, Devin B. Lowe, Robert P. Edwards, Pawel Kalinski, Walter J. Storkus

Subjects: “…anti-PD-L1…”
Get full text